BioCryst Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: BCRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BioCryst Pharmaceuticals free cash flow
In the quarter ended Jun 30, 2026, BioCryst Pharmaceuticals generated $104.3 million of operating cash flow and spent $209,000 on capital expenditures. That left free cash flow of $104.1 million, a free-cash-flow margin of 47.7% of revenue. Free cash flow was up 153.2% from the prior year's $41.1 million.
Summary generated from market data by MetaCap's automated system. Methodology
BioCryst Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 78.39M | -721.81M | 245.84M | 12.90M | 5.08M | 32.00K | -26.80M | -14.03M | -12.67M | -35.38M | -61.73M | -36.15M |
| Net Income growth (YoY) | +1441.69% | -2255762.50% | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 513.00K | 461.00K | 394.00K | 335.00K | 329.00K | 331.00K | 309.00K | 311.00K | 320.00K | 306.00K | 423.00K | 420.00K |
| Stock-Based Compensation | 14.69M | 16.03M | 23.79M | 18.60M | 21.30M | 21.37M | 21.34M | 17.25M | 13.17M | 13.65M | 16.49M | 12.28M |
| Change in Working Capital | 15.21M | -62.93M | 17.41M | 16.95M | 24.75M | -47.58M | 11.52M | 12.11M | 14.77M | -48.52M | 47.44M | -16.20M |
| Operating Cash Flow | 104.34M | -61.79M | 291.96M | 41.62M | 41.30M | -27.52M | -5.21M | 8.24M | -1.37M | -53.68M | -8.92M | -19.90M |
| Capital Expenditures | -209.00K | -403.00K | -802.00K | -1.34M | -179.00K | -143.00K | -675.00K | -59.00K | -155.00K | -235.00K | -554.00K | -987.00K |
| Investing Cash Flow | -110.15M | -268.65M | -83.49M | 13.57M | 29.13M | 27.09M | 17.80M | 8.49M | -2.45M | 28.76M | -28.47M | 23.12M |
| Debt Issued | 0 | 400.00M | — | — | 0 | 0 | 0 | 0 | — | — | 0 | 0 |
| Debt Repaid | — | — | -184.15M | -46.34M | — | — | 0 | 0 | — | — | — | — |
| Financing Cash Flow | -11.15M | 412.55M | -217.96M | -58.81M | -73.69M | 529.00K | -4.02M | 1.27M | -1.97M | -1.05M | -3.17M | 1.23M |
| Net Change in Cash | -16.99M | 82.04M | — | — | -16.96M | 558.00K | 7.26M | 18.86M | -5.93M | -26.32M | -40.04M | 4.70M |
| Free Cash Flow | 104.13M | -62.19M | 291.16M | 40.28M | 41.12M | -27.66M | -5.89M | 8.19M | -1.52M | -53.92M | -9.47M | -20.88M |
This table shows 12 quarterly periods of BioCryst Pharmaceuticals's cash flow statement, from Q2 2026 back to Q3 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow BCRX's reporting calendar. What is a cash flow statement?